All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
This is the third episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Alex Herrera, City of Hope Comprehensive Cancer Center, Duarte, US, Does ctDNA add value to current prognostic markers for identifying high-risk patients?
ctDNA can be a useful tool for identifying residual disease after the initiation of treatment, and it can also be used as a prognostic factor for outcome with a particular treatment.
Does ctDNA add value to current prognostic markers for identifying high-risk patients?
In this podcast, Herrera discusses the results of a phase Ib/II study evaluating the prognostic value of ctDNA for identifying patients with relapsed/refractory diffuse large B-cell lymphoma, receiving polatuzumab + bendamustine and rituximab versus bendamustine and rituximab alone, at higher risk for disease progression.
For the first episode in this series click here.
For the second episode in this series click here.
FDA approval granted to polatuzumab vedotin in combination with bendamustine and rituximab for R/R DLBCL
The United States (US) Food & Drug Administration (FDA) have granted accelerated approval to polatuzumab vedotin (Pola) in combination with...
NICE recommends polatuzumab vedotin with rituximab and bendamustine for R/R diffuse large B-cell lymphoma
The National Institute for Health and Care Excellence (NICE) has recommended in a published draft guidance, polatuzumab vedotin with rituximab...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox